Peter Blume-Jensen insider trades: Acrivon Therapeutics (ACRV) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Peter reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | ACRV | ↓ Sell | 14,036 | $2.21 | $31K | Direct | Aug 27, 2026 (2d) |
| Aug 18, 2026 | ACRV | ↓ Sell | 1,229 | $2.01 | $2K | Direct | Aug 20, 2026 (2d) |
| Aug 18, 2026 | ACRV | ↓ Sell | 484 | $2.01 | $973 | Indirect | Aug 20, 2026 (2d) |
| Jan 14, 2026 | ACRV | ↑ Buy | 49,000 | $1.68 | $82K | Direct | Jan 16, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACRV insiders
Open-market trades in the last 12 months
About Peter Blume-Jensen's insider trades
Peter Blume-Jensen is President and CEO at Acrivon Therapeutics (ACRV). Since Jan 14, 2026, Peter has reported 1 open-market purchase worth $82K and 3 sales worth $34K on SEC Form 4. In the last 12 months: 1 buy ($82K) and 3 sales ($34K).
Their filings also include shares withheld for taxes (18 filings), grants and awards (6 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACRV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.